What are the fundraising trends in the biotechnology market?
In our biotechnology market deck, you will find everything you need to understand the market
SUMMARY
We analyzed the global biotechnology market between January 2024 and July 2026, using only publicly disclosed equity rounds raised by pure-play biotechnology companies. The dataset filters for rounds of at least $300,000, disclosed deal sizes, equity financing only, and companies focused on therapeutics discovery, cell therapy, gene editing, synthetic biology, diagnostics, or bioprocessing tools.
The freshest read shows a stronger biotechnology market in 2026 than in the comparable 2025 period. Biotechnology companies raised about $11.9B across 88 deals in the first part of 2026, versus about $8.0B across 64 comparable-period deals in 2025.
The full-year comparison shows that the recovery had already started before 2026. Full-year 2025 reached about $14.8B across 124 deals, compared with about $13.4B across 157 deals in 2024, which means the market became more capital-intensive even while fewer companies raised.
The biotechnology market is still top-heavy, but not entirely dependent on one company. In 2026 so far, the largest deal represents 17.7% of capital, the top 3 deals represent 28.0%, and the top 10 deals represent 44.3%, while the bottom half of deals still accounts for 20.3% of total dollars.
Round sizes remain very large by venture standards. The median round in 2026 so far is about $85M, and the average round is about $135M, which confirms that the visible public dataset is dominated by institutional-quality biotech financings rather than small undisclosed seed rounds.
Therapeutics Discovery Platforms dominate the biotechnology market. They account for 65 of 88 current-year deals and about $9.7B of 2026 capital, equal to roughly 82% of all dollars raised in the dataset.
Series B is the clearest stage signal in the current market. Series B rounds represent about $5.1B, or 43% of 2026 capital so far, which means investors are leaning toward companies that have moved beyond launch narratives but are not necessarily de-risked late-stage businesses.
New-company formation remains healthy, but it is no longer taking the largest share of capital. First financings represent about 36% of 2026 deals and about 26% of capital, which means new biotechnology companies are still being created, while the biggest checks are shifting toward follow-ons.
North America remains the center of gravity, but Europe and Asia-Pacific are gaining share. North America holds about 61% of current-year capital, Europe about 29%, and Asia-Pacific about 10%, making 2026 more geographically distributed than 2025 without becoming truly global.
The strongest market interpretation is selective expansion. More companies are raising, more capital is being deployed, and more regions are visible, but the largest rewards still go to therapeutics-heavy companies with credible assets, strong syndicates, and clear paths toward clinical or strategic validation.
This chart, featured in our biotechnology market deck, breaks down revenue across customer segments in the biotechnology market
Is more or less capital going into the biotechnology market?
More capital is going into the biotechnology market in the current 2026 read, and the increase is visible in both dollars and deal count. The market raised about $11.9B across 88 deals in the first part of 2026, compared with about $8.0B across 64 deals over the comparable period in 2025.
That means capital is up roughly 49% and deal count is up roughly 38%. The important point is that both indicators moved upward, which makes the current increase more convincing than a market where one giant round creates all of the headline growth.
The full-year comparison adds useful context. In 2025, the biotechnology market raised about $14.8B across 124 deals, compared with about $13.4B across 157 deals in 2024. So 2025 already had more capital than 2024, but with fewer companies raising.
The practical takeaway is that the biotechnology market has moved from a selective recovery in 2025 into a more active and capital-intensive first half of 2026. It is not just that biotech is suddenly back; it is that investors have become more willing to fund difficult biology again, under stricter proof conditions.
For the broader dataset behind this capital-flow comparison, see the full biotechnology market report.
Is biotechnology funding activity driven by more deals or larger rounds?
Biotechnology funding activity is being driven by both more deals and larger aggregate capital deployment, but the stronger signal is higher capital intensity per funded company. The biotechnology market has more deals in 2026 than in the comparable 2025 period, yet it remains a market dominated by large institutional rounds.
The current-year dataset contains 88 deals versus 64 over the comparable 2025 period. That is real breadth improvement. But the capital increase is larger than the deal-count increase, with 2026 so far at about $11.9B versus about $8.0B in the comparable 2025 window.
The round-size data confirms the point. The average 2026 round is about $135M, while the median is about $85M. A high median matters because it shows that the funding environment is not only a tiny cluster of outlier mega-rounds; typical visible rounds are also large.
The full-year 2025 versus 2024 comparison is even clearer. In 2025, there were fewer deals than in 2024, but more capital. That means 2025 funding growth was driven mainly by larger rounds, not more companies. The 2026 signal is healthier because both deal count and capital are rising.
For deeper benchmarks on median round size, average round size, and capital concentration, see the biotechnology market deck.
Is biotechnology capital moving toward later-stage or earlier-stage companies?
Biotechnology capital is moving toward later-stage companies in 2026, after a more balanced 2025. The current-year stage split shows that Series B and later rounds are absorbing most of the dollars.
In 2026 so far, late-stage rounds, defined as Series B and later, account for about $7.7B, or 64% of capital. Early-stage rounds, defined as Seed and Series A, account for about $2.9B, or 24% of capital. Unknown and other stages account for the remainder.
Series B alone is the biggest stage by capital, with about $5.1B, or 43% of all dollars raised in 2026 so far. That is the real stage signal. Investors are paying most aggressively for companies that have moved beyond initial formation and can show stronger validation, but still have large upside.
This does not mean early-stage biotechnology is weak. Series A still represents about $2.7B, or 23% of current-year capital. The better interpretation is that the market remains open to early-stage science, while the largest pools of capital now prefer companies with prior validation, clearer assets, or more mature development plans.
This chart, featured in our biotechnology market deck, compares the main business model options for biotech platform companies
Is the biotechnology market maturing or still experimental?
The biotechnology market is maturing in financing structure, but it remains experimental at the science level. Investors are still funding difficult biology, but they are doing it through larger, more professionally syndicated companies with clearer asset paths.
The strongest maturity signal is the current stage and round-size structure. Series B is the largest stage by capital, and rounds above $50M represent more than 80% of 2026 deals. A purely experimental market would have many small seed checks and fewer large follow-ons.
At the same time, the biotechnology market is not mature in the sense of being predictable or low-risk. The largest funded categories still include therapeutics discovery, gene and RNA medicines, cell therapy, and synthetic biology. These are high-uncertainty areas with long clinical and regulatory timelines.
The honest interpretation is institutionalized experimentation. The market still takes scientific risk, but investors increasingly want that risk packaged inside companies with serious syndicates, multiple milestones, clinical proximity, or strategic pharma relevance.
Are new startups still entering the biotechnology market?
Yes, new startups are still entering the biotechnology market, and the evidence is stronger than a simple follow-on-heavy funding story would suggest. The market is not only refinancing existing companies; it is still creating new companies around assets, platforms, spinouts, and first institutional rounds.
In 2026 so far, first financings represent about 36% of deals and about 26% of capital. That is lower than 2024, when first financings represented about 47% of deals and about 53% of capital, but it is still a substantial level of new-company formation.
The comparison with 2025 is important. In full-year 2025, first financings represented about 36% of deals and 39% of capital. The share of first-financing deals has stayed broadly similar in 2026, but their capital share has fallen, which means the largest dollars are shifting toward follow-ons.
A new biotechnology startup often does not look like a tiny seed-stage software company. Many are launched with licensed assets, pharma spinouts, platform packages, repeat founders, or institutional syndicates. The biotechnology market is still creating new companies, but many of those companies are born with meaningful validation already attached.
For more detail on first financings, company formation, and follow-on activity, see the full biotechnology market report.
Are more investors entering the biotechnology market?
The biotechnology market is attracting a broad investor base, but the current evidence points more to sustained institutional participation than to a simple wave of brand-new investors. The market already had a large investor base in 2025, and 2026 shows continued breadth.
Full-year 2025 had about 464 disclosed investors and about 90 unique tier-1 investors. The 2026 dataset already has about 290 disclosed investors and about 46 tier-1 investors, despite covering only the current year to date.
Those 2026 counts should not be annualized mechanically, because investor disclosure varies by round and by source. Still, the numbers show that biotechnology remains investable for specialized life-science funds, crossover investors, pharma venture arms, and selected generalist funds.
The market is broad, but it is not democratic. Many investors can appear in a biotech syndicate, but the ability to validate and lead large rounds remains concentrated among repeat life-science specialists with technical diligence capacity.
This chart, featured in our biotechnology market deck, illustrates yearly funding for biotechnology startups
Are top investors getting more or less active in biotechnology?
Top investors remain highly active in the biotechnology market, and their participation is becoming more important as a credibility filter. The market is not fragmenting into anonymous capital; the most visible rounds repeatedly include specialist life-science investors and pharma-linked capital.
In 2026 so far, OrbiMed and RA Capital each appear in about 10 disclosed deals. Forbion appears in about 8, while Frazier Life Sciences, Qiming Venture Partners, Invus, Janus Henderson, BVF, GV, ARCH, Deep Track, Vivo, Samsara, Sofinnova, Alexandria, and SR One all recur across multiple rounds.
Full-year 2025 showed the same pattern. OrbiMed appeared in about 16 deals, RA Capital in about 15, Forbion in about 10, and Sanofi or Sanofi Ventures in at least 9. This means the top-investor signal is not new in 2026; it is a continuation of a market where recognized syndicate leaders matter.
The practical reading is simple. In biotech, investor logos are not just financing decoration. Repeat participation from high-quality biotech investors often signals that a company has passed serious scientific, clinical, and strategic diligence.
Which biotechnology subcategories are gaining momentum?
Therapeutics Discovery Platforms are gaining the most momentum in the biotechnology market, while Synthetic Biology Platforms are gaining capital momentum in a more concentrated way. Gene Editing Companies remain important, but their momentum is selective rather than indiscriminate.
In 2026 so far, Therapeutics Discovery Platforms account for about $9.7B, or 82% of capital, and 65 of 88 deals, or 74% of deal count. This is the clearest category winner in the dataset and the main reason the biotechnology market looks stronger overall.
Synthetic Biology Platforms have a different profile. They represent only 3 deals in 2026 so far, but those deals account for about $528M, or 4.4% of capital. That means investors are not broadly funding every synthetic biology company, but they are willing to write large checks for the few platforms they believe are credible.
Gene Editing Companies remain strategically meaningful, with about $986M across 11 deals in 2026 so far. The category is durable, but disciplined. Investors still like genetic medicine, RNA delivery, and editing-adjacent approaches, but the capital share does not suggest an indiscriminate boom.
For a deeper breakdown by therapeutics, gene editing, synthetic biology, cell therapy, diagnostics, and bioprocessing, see the market report covering biotechnology subcategories.
Which biotechnology subcategories are losing momentum?
Diagnostic Technology Firms and Bioprocessing Tool Providers are losing visible momentum inside this biotechnology funding universe. Cell Therapy Developers are not disappearing, but they are under-indexing relative to broader therapeutics platforms.
The clearest negative signal is diagnostics. The 2026 dataset records no qualifying Diagnostic Technology Firm deals, even though diagnostics had visible activity in prior years. That does not prove no diagnostics companies raised anywhere, but it does show that diagnostics disappeared from this public equity dataset.
Bioprocessing Tool Providers are also weak. In 2026 so far, the category has just 1 deal and about $40M, equal to only 0.3% of capital. That is striking because bioprocessing matters operationally, but the venture market is rewarding therapeutic upside much more than infrastructure leverage.
Cell Therapy Developers remain funded, with 8 current-year deals and about $596M. But the category’s capital share is below its deal share, which suggests selective funding rather than broad enthusiasm. The market is willing to fund cell therapy when differentiation, manufacturing credibility, or clinical relevance is clear.
This chart, featured in our biotechnology market deck, looks at Vertex’s strategy in biotechnology
Which regions are gaining momentum in biotechnology funding?
Europe and Asia-Pacific are gaining relative momentum in biotechnology funding, while North America remains the dominant region by both capital and deal count. The biotechnology market is still anchored in North America, but the current-year evidence shows a more distributed capital base than in 2025.
In 2026 so far, North America accounts for about $7.3B, or 61% of capital. Europe accounts for about $3.5B, or 29%, and Asia-Pacific accounts for about $1.1B, or nearly 10%.
Over the comparable period in 2025, North America had about 66% of capital, Europe about 22%, Asia-Pacific about 8%, and the Middle East about 2%. So Europe and Asia-Pacific have both gained share in 2026 so far.
Deal count makes the regional shift feel more grounded. North America still has 59 of 88 current-year deals, but Europe has 17 and Asia-Pacific has 12. Asia-Pacific’s 12 deals matter because they show broader activity than a single outlier financing would imply.
Which regions are losing momentum in biotechnology funding?
North America is losing relative share in biotechnology funding, but not absolute importance. The region still dominates the market, yet Europe and Asia-Pacific are taking a larger share of current-year capital than they did in 2025.
North America’s capital share moved from about 69% in full-year 2025 to about 61% in 2026 so far. That is a meaningful share decline, but it should not be misread as weakness. North America still raised more capital than all other regions combined in the current-year dataset.
The Middle East is also weaker in the current dataset. In 2025, the region had one large qualifying biotechnology deal worth about $165M. In 2026 so far, it has no qualifying deals in the dataset.
Latin America and Africa remain absent across the visible qualifying dataset. That is not simply a short-term loss of momentum; it is a structural signal that public, venture-backed biotechnology financing remains highly concentrated in regions with specialized capital, research institutions, clinical infrastructure, and pharma networks.
Is biotechnology becoming more global or regionally concentrated?
The biotechnology market is becoming modestly more global in 2026, but it remains regionally concentrated around North America and Europe. The market is not global in the same way software can be global, because biotechnology depends heavily on scientific ecosystems, clinical infrastructure, regulatory expertise, and specialized investors.
The current-year data points toward a broader map. North America’s share is lower than in 2025, while Europe is approaching 30% of capital and Asia-Pacific is approaching 10%. That is a healthier global split than a market where North America takes nearly all dollars.
But the market is still concentrated. North America has 67% of 2026 deals and 61% of capital. Europe is the only other region with a very large capital share, and Asia-Pacific is visible but smaller. Latin America, the Middle East, and Africa have no qualifying 2026 deals in this dataset.
The best conclusion is more global at the margin, still concentrated structurally. The biotechnology market is broadening among credible biotech hubs, not becoming evenly distributed across the world.
For the full regional view across North America, Europe, Asia-Pacific, and other regions, see the deeper analysis of the biotechnology market.
This chart, featured in our biotechnology market deck, shows how platform therapeutics have driven growth in the biotechnology market over time
Is biotechnology capital moving toward proven winners or new opportunities?
Biotechnology capital is moving toward both proven winners and new opportunities, but 2026 tilts more toward proven winners than 2025 did. The current-year funding mix has a strong follow-on and Series B-plus character, while still supporting new company formation.
In 2026 so far, first financings account for about 36% of deals but only 26% of capital. That means new opportunities are still entering the market, but follow-on companies are taking the larger share of dollars.
The stage split points in the same direction. Series B and later rounds account for about 64% of 2026 capital. Investors are still willing to back new companies, but the biggest checks now favor companies with prior validation, licensed assets, clearer pipelines, or repeat teams.
In 2024, first financings were much stronger by capital share, representing about 53% of dollars. In 2025, they still represented about 39%. The shift to about 26% in 2026 shows that the market is moving from formation-led to validation-led.
Is the biotechnology market becoming winner-takes-most?
The biotechnology market is becoming winner-takes-more, but not fully winner-takes-most. Capital is concentrated at the top, yet the bottom half of the dataset still captures enough capital to show that funding breadth remains real.
In 2026 so far, the largest deal represents 17.7% of total capital. The top 3 deals represent 28.0%, the top 5 represent 33.3%, and the top 10 represent 44.3%. That is a top-heavy market, but not a market where one or two companies absorb everything.
The bottom half of deals represents about 20.3% of capital. That matters because it shows there is still a long tail of funded companies. The biotechnology market is not only recycling dollars into a tiny winner set.
The better description is selective scale. Investors are willing to fund many companies, but they reserve the largest checks for platforms or assets that look capable of surviving clinical, regulatory, and strategic pharma scrutiny.
Is the next wave of biotechnology winners becoming visible?
Yes, the next wave of biotechnology winners is becoming visible, but only as a financed cohort, not yet as a clinically proven cohort. In biotechnology, large Series A and Series B rounds often reveal which companies elite investors believe could become category leaders.
The 2026 data points most clearly to Series A and Series B cohorts. Series A accounts for 28 deals and about $2.7B, while Series B accounts for 30 deals and about $5.1B. Together, those stages form the core of the current winner pipeline.
The most visible themes include therapeutics platforms with concrete assets, genetic and RNA medicines with delivery credibility, selective synthetic biology platforms, and asset-plus-platform companies that can create multiple shots on goal. These companies are not just selling technology narratives; they are trying to connect platform logic to development paths.
The caution is important. Financing visibility is not clinical success. The biotechnology market often crowns paper winners years before efficacy, safety, regulatory, or commercial outcomes are proven. The next wave is visible as an investor-backed cohort, not as a validated product cohort.
For more context on the emerging winner cohort, see the full market view on biotechnology winners.
As this chart shows, and as featured in our biotechnology market deck, search interest in biotech has been trending upward
Is the biotechnology funding landscape fragmenting or consolidating?
The biotechnology funding landscape is consolidating around dominant categories, large rounds, and repeat investors, even though the company count remains broad. The market has many funded companies, but the real capital power is concentrated in therapeutics platforms and familiar specialist syndicates.
Category concentration is the clearest consolidation signal. In 2026 so far, Therapeutics Discovery Platforms account for about 74% of deals and 82% of capital. All other categories combined account for less than 20% of capital.
Investor concentration is also visible. The same names recur across years: OrbiMed, RA Capital, Forbion, ARCH, Novo Holdings, Frazier, Qiming, GV, Sanofi Ventures, Pfizer Ventures, and other specialized life-science investors. These investors help decide which scientific narratives become financeable.
At the company level, however, the market is not fully consolidated. There are 88 funded companies in 2026 so far and 124 in full-year 2025. The honest interpretation is that the biotechnology market is broad at the company layer and concentrated at the capital-allocation layer.
Where is investor attention shifting in biotechnology?
Investor attention in the biotechnology market is shifting toward therapeutics platforms with clearer asset paths, later-stage validation, genetic and RNA medicine delivery, selective synthetic biology, and regionally broader opportunities in Europe and Asia-Pacific. It is shifting away from diagnostics, bioprocessing tools, and undifferentiated platform-only stories.
The biggest attention shift is toward therapeutics that look fundable as products, not just technologies. In 2026 so far, Therapeutics Discovery Platforms captured about $9.7B out of $11.9B. That tells us investors are prioritizing drug-development upside over tools, diagnostics, and infrastructure.
Investor attention is also shifting toward later-stage validation. Series B is the largest capital stage in the current-year dataset, and late-stage capital is materially higher than early-stage capital. Investors are not simply chasing novelty; they want companies that have progressed far enough to justify larger risk-bearing rounds.
Regionally, attention is shifting somewhat toward Europe and Asia-Pacific. North America still dominates, but Europe’s capital share is meaningfully higher than in 2025, and Asia-Pacific has a larger visible current-year deal base. The biotechnology market is becoming more international among credible biotech hubs, even if it is not globally even.
For real-time tracking of how investor attention is moving across categories, stages, regions, and repeat syndicates, see the biotechnology market report.
INSIGHTS
The insights below come from reviewing publicly disclosed equity rounds in the biotechnology market between January 2024 and July 2026, with the current-year read based on 2026 year-to-date funding.
- The biotechnology market’s recovery is not a generic venture recovery; it is a therapeutics-led recovery. When one category captures more than 80% of current-year capital, the market’s health depends primarily on drug-development confidence, not broad life-science tooling demand.
- The 2026 acceleration is stronger than a single-outlier story because both capital and deal count increased versus the comparable 2025 period. A market driven only by one mega-round would show capital growth without deal-count growth.
- The full-year 2025 versus 2024 comparison shows that the market became more capital-intensive before it became more active. That sequence suggests investors first concentrated capital into fewer perceived winners, then reopened activity more broadly in 2026.
- Series B is the most important current-stage signal in the biotechnology market. Series B dominance means investors are rewarding companies that have moved past launch narratives, but are not necessarily late enough to be de-risked.
- The 2026 market is not early-stage weak; it is follow-on strong. Seed and Series A still raise large amounts, but Series B and later rounds have become the main capital sink.
- First financings remaining around one-third of deals means new-company formation is healthy. The decline in first financings’ capital share means new companies are no longer taking the largest share of dollars.
- The market is moving from formation-led to validation-led. In 2024 and 2025, large launches were central; in 2026, follow-ons and Series B rounds carry more of the capital burden.
- The biotechnology market is top-heavy, but not brittle. The top 10 current-year deals capture about 44% of capital, while the bottom half still captures about 20%, which means there is a real long tail of fundable companies.
- The absence of current-year Diagnostic Technology Firm deals is more meaningful than a small decline would have been. A zero in a category that had prior-year activity suggests investor attention has sharply rotated away from diagnostics in this public equity universe.
- Bioprocessing tools remain underfunded relative to their operational importance. The market is rewarding therapeutic upside more than infrastructure leverage.
- Cell therapy is funded selectively rather than expansively. The category still raises meaningful money, but its capital share is below its deal share, which implies investors are cautious about manufacturing and clinical execution risk.
- Gene editing and RNA medicine remain strategically important but financially disciplined. The category has enough deals to matter, but not enough capital share to suggest indiscriminate enthusiasm.
- Synthetic biology has a high-capital, low-count profile. That means investors are not broadly buying the category; they are selectively backing a few large, credible platforms.
- North America is losing share but not leadership. A decline from roughly 69% of full-year 2025 capital to roughly 61% of 2026 capital still leaves North America as the center of gravity.
- Europe’s current-year gain is one of the most important regional signals. Europe approaching 30% of current-year capital suggests the biotechnology market is broadening beyond the United States without becoming globally diffuse.
- Asia-Pacific’s increased 2026 deal visibility matters because it is not only a capital-share story. Twelve Asia-Pacific deals in 2026 so far indicate broader participation than a single large financing would.
- Latin America and Africa being absent across the visible qualifying dataset is a structural market signal. Biotechnology venture financing still depends heavily on ecosystems that combine specialized capital, clinical infrastructure, universities, pharma access, and regulatory credibility.
- Repeat investor participation is a stronger signal in biotech than in most software markets. In biotechnology, investors with technical diligence capacity act as validators of the science, not just providers of capital.
- Pharma venture arms appearing repeatedly should be treated as strategic validation. Their participation often signals that a modality, target, or asset class has partnership relevance.
- The market is not rewarding platform claims by themselves. The best-funded companies tend to combine platform optionality with concrete assets, disease focus, or clinical paths.
- The biotechnology market’s center of gravity is moving toward asset-plus-platform companies. Pure assets can be too narrow, while pure platforms can be too speculative; the funded sweet spot is a credible asset with platform expansion logic.
- The market is consolidating at the capital layer but not at the company layer. Many companies still raise money, but the biggest checks flow through fewer categories, fewer regions, and familiar syndicate leaders.
This chart, featured in our biotechnology market deck, shows how at-home genetic testing technology has evolved over time
OUR METHODOLOGY TO BUILD THIS TRACKER
We built this biotechnology funding tracker by reviewing publicly disclosed equity rounds raised by pure-play biotechnology companies between January 2024 and July 2026. A company counts as pure-play when more than 80% of its activity is dedicated to modern biological science or engineering used to create or improve medical and life-science outcomes.
We applied four core filters to build the dataset. First, we only included equity rounds, so grants, debt, structured financings, SPAC transactions, acquisitions, and business combinations are excluded. Second, we only counted rounds of $300,000 or more. Third, we only kept pure-play biotechnology companies in the covered categories. Fourth, every entry had to be supported by a direct company announcement, press release, tier-1 media report, specialized industry source, or relevant regional publication.
The covered categories are Therapeutics Discovery Platforms, Cell Therapy Developers, Gene Editing Companies, Synthetic Biology Platforms, Diagnostic Technology Firms, and Bioprocessing Tool Providers. We excluded routine healthcare delivery, conventional pharmaceuticals or chemicals not enabled by biotechnology, generic medtech devices without a molecular or biological core, and agriculture or industrial bioapplications unless they clearly fit the medical or life-science scope.
Undisclosed-amount rounds are excluded because including them would distort dollar-based metrics such as total capital, average round size, median round size, category share, stage share, and regional share. Privately raised rounds that were never publicly announced are necessarily missing, which is a known limitation of any public-source biotechnology funding tracker.
Related blog posts
- What has changed recently in the biotechnology market?
- The latest news in the biotechnology market
- What is the true size of the biotechnology market?
- The latest funding news in the biotechnology market
- How funding activity has changed in the biotechnology market
- The startups that have raised the most funding in the biotechnology market
- The most highly valued startups in the biotechnology market
